Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.65 |
| ▸ | MMP8 known ✓ | P22894 | 1/20 | 0.41 |
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.41 |
| ▸ | AGTR1 known ✓ | P30556 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | IDO1 | P14902 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.45 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.45 |
| ▸ | FNTA | P49354 | 1/20 | 0.42 |
| ▸ | FNTB | P49356 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL486107 | 0.97 | TDP1 (0.68) | CYP3A4TDP1CYP1A2IDO1LMNA | |
| Biphenyl SCHEMBL27571445 | 0.89 | TDP1 (0.82) | CYP3A4TDP1CYP1A2IDO1LMNA | |
| Hydrochloric Acid SCHEMBL31628644 | 0.89 | TDP1 (0.53) | CYP3A4TDP1CYP1A2IDO1LMNA | |
| Hydrochloric Acid SCHEMBL30096476 | 0.89 | TDP1 (0.53) | CYP3A4TDP1CYP1A2IDO1LMNA | |
| Biphenyl SCHEMBL27808430 | 0.86 | TDP1 (0.78) | CYP3A4TDP1CYP1A2IDO1LMNA | |
| Hydrochloric Acid SCHEMBL30583826 | 0.86 | TDP1 (0.50) | CYP3A4TDP1CYP1A2IDO1LMNA | |
| SCHEMBL4094372 | 0.86 | TDP1 (0.56) | CYP3A4TDP1CYP1A2IDO1LMNA | |
| SCHEMBL10387580 | 0.85 | CYP3A4 (0.67) | CYP3A4TDP1CYP1A2IDO1LMNA | |
| Biphenyl SCHEMBL185563 | 0.83 | LMNA (0.56) | CYP3A4TDP1CYP1A2IDO1LMNA | |
| Phenylhydrazine SCHEMBL304025 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180088124-A1 | DETECTION METHOD FOR QUATERNARY AMMONIUM COMPOUND HAVING y-CARBOXYL GROUP | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2018-03-29 | — | — | US | claimed |
| CN-119552120-A | Pyrazole and imidazole compounds for inhibiting IL-17 and rory | 里亚塔医药公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-112654610-B | Pyrazole and imidazole compounds for inhibiting IL-17 and rory | 里亚塔医药公司 | 2024-12-24 | — | — | CN | disclosed |
| US-20240360084-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS FOR INHIBITION OF IL-17 AND RORGAMMA | REATA PHARMACEUTICALS INC (US) | 2024-10-31 | — | — | US | disclosed |
| US-11993574-B2 | Pyrazole and imidazole compounds for inhibition of IL-17 and RORgamma | REATA PHARMACEUTICALS, INC (US) | 2024-05-28 | — | — | US | disclosed |
| US-20210292281-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS FOR INHIBITION OF IL-17 AND RORGAMMA | REATA PHARMACEUTICALS, INC. (US) | 2021-09-23 | — | — | US | disclosed |
| US-11016096-B2 | Detection kit for quaternary ammonium compound having γ-carboxyl group | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2021-05-25 | — | — | US | disclosed |
| EP-3807265-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS FOR INHIBITION OF IL-17 AND RORGAMMA | Reata Pharmaceuticals, Inc. (US) | 2021-04-21 | — | — | EP | disclosed |
| CN-112654610-A | Pyrazole and imidazole compounds for inhibiting IL-17 and ROR gamma | 里亚塔医药公司 | 2021-04-13 | — | — | CN | disclosed |
| US-20200283681-A1 | DETECTION KIT FOR QUATERNARY AMMONIUM COMPOUND HAVING y-CARBOXYL GROUP | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2020-09-10 | — | — | US | disclosed |
| US-10703969-B2 | Detection method for quaternary ammonium compound having γ-carboxyl group | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2020-07-07 | — | — | US | disclosed |
| CN-109705126-A | A kind of compound and application for organic electroluminescence device | 赛洛普（武汉）科技有限公司 | 2019-05-03 | — | — | CN | disclosed |
| US-20180088124-A1 | DETECTION METHOD FOR QUATERNARY AMMONIUM COMPOUND HAVING y-CARBOXYL GROUP | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2018-03-29 | — | — | US | disclosed |
| CN-100387594-C | Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 | MERCK & CO INC (US) | 2008-05-14 | — | — | CN | disclosed |
| US-20060194807-A1 | Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 | MERCK & CO., INC. | 2006-08-31 | — | — | US | disclosed |
| CN-1795184-A | Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 | MERCK & CO INC (US) | 2006-06-28 | — | — | CN | disclosed |
| EP-1613614-A2 | DI-ARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Merck & Co., Inc. (US) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004089303-A2 | DI-ARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO., INC. (US) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292281-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS FOR INHIBITION OF IL-17 AND RORGAMMA | RORC, RORB, RORA | PTGS2 789/4885MMP8 2099/4885CA2 3135/4885 |
| US-20240360084-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS FOR INHIBITION OF IL-17 AND RORGAMMA | RORC, RORB, RORA | PTGS2 789/4885MMP8 2099/4885CA2 3135/4885 |
| US-11993574-B2 | Pyrazole and imidazole compounds for inhibition of IL-17 and RORgamma | RORC, RORB, RORA | PTGS2 789/4885MMP8 2099/4885CA2 3135/4885 |
| US-20060194807-A1 | Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 | GRM5, GRM1, GRIK5 | PTGS2 2804/4885MMP8 4852/4885CA2 4021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.